Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension

Completed · Phase 2 · Has a placebo group

Conditions studied: Hypertension

In brief

Liquid potassium-magnesium citrate (KMgCit) as a pharmaceutical formulation will lower blood pressure among patients with pre- or Stage I hypertension on their customary diet.

Key facts

Study ID

NCT01682837

Run by

University of Texas Southwestern Medical Center

People needed

35

Starts

2012-10-01

Expected to finish

2015-03-01

Last updated by the study team

2017-04-28

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men or women > 21 years of age
• Any Race/Ethnicity
• Pre- or Stage I hypertension (BP >= 120/80 and <= 159/99)

You may not qualify if…

• Diabetes mellitus
• Renal impairment (serum creatinine > 1.4 mg/dL)
• Any heart diseases such as congestive heart failure or sustained arrhythmia
• Chronic NSAID use
• Treatment with diuretics
• Gastroesophageal reflux disease (GERD) requiring treatment with acid reducing agents or antacid more than once a week
• Esophageal-gastric ulcer
• Chronic diarrhea
• Hyperkalemia (serum > 4.6 meq/L for patients on angiotension-converting-enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), serum K > 5.0 meq/L for patient not on ACE inhibitors or ARBs)
• Abnormal liver function test (aspartate transaminase (AST) or alanine transaminase (ALT) above upper limit of normal range)
• Subjects who require any potassium supplement on a regular basis from any reasons
• Pregnancy
• History of major depression, bipolar disorder, or schizophrenia

Where it is running

• Hypertension Clinic - UT Southwestern Medical Center at Dallas — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.